|Bid||8.10 x 1400|
|Ask||8.15 x 800|
|Day's Range||8.05 - 8.25|
|52 Week Range||5.82 - 14.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.10|
Aduro Biotech, Inc. (ADRO) today announced the recent initiation of a Phase 1b study of ADU-214 (JNJ-64041757) in combination with nivolumab for the treatment of advanced lung cancer. ADU-214 is an immunotherapy based on Aduro’s live, attenuated double-deleted Listeria (LADD) technology platform in development for the treatment of advanced or metastatic non-small cell lung cancer. Janssen Biotech, Inc. (Janssen), Aduro’s license partner for ADU-214, is conducting the global trial.
Featured today on WallStEquities.com is the Biotechnology industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are four equities: Adaptimmune Therapeutics PLC (NASDAQ: ADAP), Aduro BioTech Inc. (NASDAQ: ADRO), Advaxis Inc. (NASDAQ: ADXS), and Adverum Biotechnologies Inc. (NASDAQ: ADVM).
Aduro (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, May 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Churchill ...
Aduro Biotech, Inc. (ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV on Thursday, May 17, 2018, at 9:35 am Pacific Time. To access the live webcast and subsequent archived recording of this and other company presentations, please visit Aduro's website at www.aduro.com. Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that are intended to transform the treatment of challenging diseases.
Aduro's (ADRO) loss in Q1 narrows from the estimate. Moreover, revenues top the same and surge substantially year over year on receipt of a milestone payment.
On a per-share basis, the Berkeley, California-based company said it had a loss of 28 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
BERKELEY, Calif., May 02, 2018-- Aduro Biotech, Inc. today reported financial results for the first quarter ended March 31, 2018. Net loss for the first quarter of 2018 was $21.5 million, or $0.28 per ...
Aduro Biotech, Inc. (ADRO) today presented preliminary observations from a case study of a patient with metastatic colorectal cancer treated in Aduro’s ongoing Phase 1 study of its personalized neoantigen-based immunotherapy (pLADD). This Phase 1 proof-of-concept study is designed to evaluate the safety and tolerability of pLADD immunotherapy in adults with metastatic colorectal cancer that is microsatellite stable (MSS). The immunological data presented demonstrated that neoantigens isolated and sequenced from the patient’s tissue samples, and engineered into a personalized immunotherapy, induced neoantigen-specific CD8+ T cells undetectable before pLADD treatment started.
BERKELEY, Calif., April 17, 2018-- Aduro Biotech, Inc. today announced that data from three of the company’ s programs were presented at the American Association for Cancer Research this week. Updated ...
BERKELEY, Calif., April 02, 2018-- Aduro Biotech, Inc. today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the H.C. Wainwright Annual Global ...
Three Chinese funds are backing this San Francisco startup that looks to tap some of the emerging areas of cancer immunotherapy.
The Berkeley, California-based company said it had a loss of 34 cents per share. Losses, adjusted for pretax gains, were 35 cents per share. The results beat Wall Street expectations. The average estimate ...
* U.S. move to slap tariffs on certain imports weighs on sentiment * Philippines retreats from record high, Q4 GDP growth lags f'cast By Nicole Pinto Jan 23 (Reuters) - Most Southeast Asian stock markets ...